Breast Cancer

NHCPRC Guidelines

National guidelines for diagnosis and treatment of breast cancer 2022 in China (English version)
National Health Commission of the People’s Republic of China
Pages: 151-175 HTML

Research Highlight

Recent advances in systematic therapy of breast cancer: Chinese contribution for international progress
Yan Wang,Binghe Xu
Pages: 587-591 HTML

Original Article

Clinicopathological and molecular features of HR+/HER2− breast cancer patients with distinct endocrine resistance patterns
Siwei Zhang,Han Wang,Hang Zhang,Qingyuan Zhuang,Xiaohui Zhu,Yi Xiao,Yizhou Jiang
Pages: 48-65 HTML
Deep learning-based multi-task prediction of response to neoadjuvant chemotherapy using multiscale whole slide images in breast cancer: A multicenter study
Qin Wang,Feng Zhao,Haicheng Zhang,Tongpeng Chu,Qi Wang,Xipeng Pan,Yuqian Chen,Heng Zhou,Tiantian Zheng,Ziyin Li,Fan Lin,Haizhu Xie,Heng Ma,Lan Liu,Lina Zhang,Qin Li,Weiwei Wang,Yi Dai,Ruijun Tang,Jigang Wang,Ping Yang,Ning Mao
Pages: 28-47 HTML
HER2-low status improves prognosis prediction in breast cancer patients receiving neoadjuvant treatment: A comparison of pathological stage, modified CPS+EG scoring system, and Neo-Bioscore
Yujie Lu,Siji Zhu,Chenghui Wu,Xiaochun Fei,Kunwei Shen,Xiaosong Chen
Pages: 729-741 HTML
Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors
Jialin Zhang,Gengshen Yin,Chunmiao Ye,Man Feng,Changhua Ji,Wenzhong Zhou,Fei Wang,Lixiang Yu,Shuya Huang,Zhigang Yu
Pages: 124-137 HTML
A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
Pin Zhang,Lin Wang,Yueying Zhen,Zhihong Wang,Hesheng Zhang,Richard Jones,Binghe Xu
Pages: 46-54 HTML
Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study
Yaping Yang,Liang Jin,Yudong Li,Nanyan Rao,Chang Gong,Shunrong Li,Jiannan Wu,Jinghua Zhao,Linxiaoxiao Ding,Fengxia Gan,Jun Zhang,Ruifa Feng,Zhenzhen Liu,Qiang Liu
Pages: 55-65 HTML
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu,Huiping Li,Zefei Jiang,Lin Gu,Jinhai Tang,Hui Xie,Yueyin Pan,Yunjiang Liu,Shude Cui,Xiaojia Wang,Li Cai,Yiqiong Zhang,Huadong Zhao,Zhimin Shao
Pages: 592-600 HTML
Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer
Dan Lyu,Binliang Liu,Bo Lan,Xiaoying Sun,Lixi Li,Jingtong Zhai,Haili Qian,Fei Ma
Pages: 343-352 HTML

Review Article

Breast cancer: Epidemiology, risk factors and screening
Hangcheng Xu,Binghe Xu
Pages: 565-583 HTML
Advances in regional nodal management of early-stage breast cancer
Zhao Bi,Yongsheng Wang
Pages: 215-225 HTML

Editorial

Adaptive neoadjuvant endocrine therapy screens out prime population of ribociclib intensive adjuvant therapy
Zhao Bi,Tongyue Ren,Yongsheng Wang
Pages: 115-117 HTML

Original Article

A multicenter study on efficacy of dual-target neoadjuvant therapy for HER2-positive breast cancer and a consistent analysis of efficacy evaluation of neoadjuvant therapy by Miller-Payne and RCB pathological evaluation systems (CSBrS-026)
Hongyu Xiang,Ling Xin,Jingming Ye,Ling Xu,Hong Zhang,Shuang Zhang,Yinhua Liu
Pages: 702-712 HTML

Perspective

Adjuvant therapy for hormone receptor-positive breast cancer: Perspective from a survey on breast cancer physicians’ acceptance of practice-changing data
Asian Institute of Clinical Oncology (AICO) Expert Panel
Pages: 191-196 HTML